NYMOX PHARMACEUTICAL CORPORATION
NASDAQ : NYMX

NYMOX PHARMACEUTICAL CORPORATION

March 08, 2005 10:34 ET

Nymox NicAlert Product Can Help Smoking Cessation


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: NYMOX PHARMACEUTICAL

NASDAQ SYMBOL: NYMX

MARCH 8, 2005 - 10:34 ET

Nymox NicAlert Product Can Help Smoking Cessation

MAYWOOD, N.J.--(CCNMatthews - Mar 8, 2005) -

The smoking cessation market presents an attractive opportunity for
Nymox Pharmaceutical's (NASDAQ: NYMX) tobacco exposure test,
NicAlert™, according to Brian Doyle, the Company's Global Sales
Manager. NicAlert™ provides a proven, easy-to-use, on-site means of
determining the level of an individual's use of or exposure to tobacco
products. NicAlert™ has received U.S. FDA clearance for medical use
for determining an individual's exposure to tobacco products such as
cigarettes, pipes, or chewing tobacco within the past 48 hours.

"NicAlert™ offers a cost-effective way of determining smoking status
right on-site," said Mr. Doyle. "It does not require any special
instruments or skills and gives accurate results within minutes. We
believe that it can be a valuable tool in the campaign to get smokers to
quit before it is too late."

Reducing the estimated 1.3 billion number of smokers worldwide is a
major goal of the WHO Framework Convention on Tobacco Control. The WHO
estimates that tobacco use and exposure currently kills 4.9 million
people a year worldwide with the annual death toll rising to an
estimated 10 million by 2020. In the U.S. alone, the Centers for Disease
Control and Prevention (CDC) estimates that smoking causes over 440,000
premature deaths annually and creates an economic loss of over $150
billion a year.

The benefits of smoking cessation programs was demonstrated by a recent
study that tracked the health of 5887 smokers for more than 14 years as
part of the Lung Health Study (Ann Intern Med. 2005 Feb 15;142:233-9).
More than 4 times as those smokers who were enrolled in a smoking
cessation program were not smoking after 5 years as compared to those
smokers not offered the program (21.7% vs. 5.4%). After 14.5 years, the
death rate for those who managed to quit was 46% lower than that of the
people who continued to smoke.

NicAlert™'s a powerful one-step technology has been found by
independent peer-reviewed studies to be an accurate, rapid and
cost-effective means of confirming smoking status. One study,
"Validating a Dipstick Method for Detecting Recent Smoking," Cancer
Epidemiology, Biomarkers & Prevention (2002; 11: 1123-1125) was authored
by Peter Gariti of the University of Pennsylvania Cancer Center Group,
Philadelphia Veterans Affairs Medical Center and the University of
Pennsylvania School of Medicine, David I. Rosenthal of the M.D. Anderson
Cancer Center in Houston, Kathleen Lindell of the University of
Pittsburgh and John Hansen-Flaschen, Joseph Shrager, Craig Lipkin,
Arthur I. Alterman and Lawrence R. Kaiser of the University of
Pennsylvania School of Medicine. The study examined the smoking status
of patients at a cancer clinic and found that the results obtained using
Nymox's tobacco product exposure test had an "excellent agreement" with
state-of-the-art sophisticated laboratory measurements but at a
substantially lower cost (over 90% less). The second study, "The
Accuracy of Self-Reported Smoking Status Assessed by Cotinine Test
Strips," Nicotine & Tobacco Research (2002; 4: 305-9) was authored by
Donna R. Parker, ScD, and Thomas M Lasater, PhD, Brown University School
of Medicine; Richard Windsor, PhD, MPH, George Washington University
Medical Center; Jeff Wilkins, MD, Greater Los Angeles VA Healthcare
Center, David Upegui, BA, Memorial Hospital of Rhode Island; and James
Heimdal, PhD, The Hoffman Heart Institute, Saint Francis Hospital and
Medical Center, Hartford, CT. The study found Nymox's product to be "an
inexpensive and rapid method to routinely biochemically confirm smoking
status at a clinical visit." The authors described the Nymox product as
a "simple, inexpensive and rapid measure to immediately confirm smoking
status in field settings."

Nymox's patented technology provides a semi-quantitative measure of
cotinine, a byproduct of the body's metabolism of nicotine. Cotinine is
widely accepted and commonly used in medical research and public health
studies to determine the extent of tobacco product exposure.

More information about Nymox is available at www.nymox.com, email:
info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as
defined in the United States Private Securities Litigation Reform Act of
1995 that involve a number of risks and uncertainties. There can be no
assurance that such statements will prove to be accurate and the actual
results and future events could differ materially from management's
current expectations. The conduct of clinical trials and the development
of drug products involve substantial risks and uncertainties and actual
results may differ materially from expectations. Promising early results
do not ensure that later stage or larger scale clinical trials will be
successful or will proceed as expected. Such factors are detailed from
time to time in Nymox's filings with the United States Securities and
Exchange Commission and other regulatory authorities.

-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    www.nymox.com